COVID-19 pandemic and transfusion medicine : the worldwide challenge and its implications
COVID-19 pandemic has imposed worldwide challenge and has significantly affected transfusion medicine. Shortage in blood products along with concerns regarding the safety of blood products have emerged. Measures to overcome these challenges have been implemented in order to decrease the demand on blood products and to encourage blood donations while taking full precautions to minimize risk of COVID-19 transmission mainly at blood banks and medical centers. Several countries have been successful in facing these new challenges. In addition, the role of plasma therapy in the treatment of COVID-19 patients, especially in severe cases, has been proposed and current studies are being conducted to determine its efficacy. Other therapeutic options are currently being explored. So far, the use of convalescent plasma is considered a promising rescue treatment to be looked at.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:100 |
|---|---|
| Enthalten in: |
Annals of hematology - 100(2021), 5 vom: 02. Mai, Seite 1115-1122 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Al Mahmasani, Layal [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Blood safety |
|---|
| Anmerkungen: |
Date Completed 19.04.2021 Date Revised 30.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00277-021-04441-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320881571 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320881571 | ||
| 003 | DE-627 | ||
| 005 | 20231225174622.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00277-021-04441-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1069.xml |
| 035 | |a (DE-627)NLM320881571 | ||
| 035 | |a (NLM)33527161 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Al Mahmasani, Layal |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 pandemic and transfusion medicine |b the worldwide challenge and its implications |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.04.2021 | ||
| 500 | |a Date Revised 30.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a COVID-19 pandemic has imposed worldwide challenge and has significantly affected transfusion medicine. Shortage in blood products along with concerns regarding the safety of blood products have emerged. Measures to overcome these challenges have been implemented in order to decrease the demand on blood products and to encourage blood donations while taking full precautions to minimize risk of COVID-19 transmission mainly at blood banks and medical centers. Several countries have been successful in facing these new challenges. In addition, the role of plasma therapy in the treatment of COVID-19 patients, especially in severe cases, has been proposed and current studies are being conducted to determine its efficacy. Other therapeutic options are currently being explored. So far, the use of convalescent plasma is considered a promising rescue treatment to be looked at | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Blood safety | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Plasma therapy | |
| 650 | 4 | |a Shortage | |
| 650 | 4 | |a Transfusion | |
| 700 | 1 | |a Hodroj, Mohammad Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Finianos, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Taher, Ali |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of hematology |d 1991 |g 100(2021), 5 vom: 02. Mai, Seite 1115-1122 |w (DE-627)NLM012918768 |x 1432-0584 |7 nnns |
| 773 | 1 | 8 | |g volume:100 |g year:2021 |g number:5 |g day:02 |g month:05 |g pages:1115-1122 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00277-021-04441-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 100 |j 2021 |e 5 |b 02 |c 05 |h 1115-1122 | ||